The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 12, 2023

Filed:

Sep. 21, 2020
Applicants:

Rajiv Jalan, London, GB;

Ugo Soffientini, London, GB;

Nigel Beaton, London, GB;

Gautam Mehta, London, GB;

Inventors:

Rajiv Jalan, London, GB;

Ugo Soffientini, London, GB;

Nigel Beaton, London, GB;

Gautam Mehta, London, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61P 1/16 (2006.01); A61K 31/27 (2006.01); A61K 31/277 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1793 (2013.01); A61K 31/27 (2013.01); A61K 31/277 (2013.01); A61K 38/07 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); G01N 33/6893 (2013.01); G01N 2800/085 (2013.01);
Abstract

The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1α) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1α) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of aberrant pyroptosis in the kidney, brain, liver or other organ of the body.


Find Patent Forward Citations

Loading…